Literature DB >> 28886001

SPOP tips the balance of BETs in cancer.

Katie A Fennell1, Mark A Dawson1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28886001     DOI: 10.1038/nm.4398

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

1.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

2.  Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.

Authors:  Jean-Philippe P Theurillat; Namrata D Udeshi; Wesley J Errington; Tanya Svinkina; Sylvan C Baca; Marius Pop; Peter J Wild; Mirjam Blattner; Anna C Groner; Mark A Rubin; Holger Moch; Gilbert G Prive; Steven A Carr; Levi A Garraway
Journal:  Science       Date:  2014-10-02       Impact factor: 47.728

Review 3.  The emerging role of speckle-type POZ protein (SPOP) in cancer development.

Authors:  Ram-Shankar Mani
Journal:  Drug Discov Today       Date:  2014-07-21       Impact factor: 7.851

4.  BET inhibitor resistance emerges from leukaemia stem cells.

Authors:  Chun Yew Fong; Omer Gilan; Enid Y N Lam; Alan F Rubin; Sarah Ftouni; Dean Tyler; Kym Stanley; Devbarna Sinha; Paul Yeh; Jessica Morison; George Giotopoulos; Dave Lugo; Philip Jeffrey; Stanley Chun-Wei Lee; Christopher Carpenter; Richard Gregory; Robert G Ramsay; Steven W Lane; Omar Abdel-Wahab; Tony Kouzarides; Ricky W Johnstone; Sarah-Jane Dawson; Brian J P Huntly; Rab K Prinjha; Anthony T Papenfuss; Mark A Dawson
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

Review 5.  The cancer epigenome: Concepts, challenges, and therapeutic opportunities.

Authors:  Mark A Dawson
Journal:  Science       Date:  2017-03-16       Impact factor: 63.714

6.  Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

Authors:  Pingzhao Zhang; Dejie Wang; Yu Zhao; Shancheng Ren; Kun Gao; Zhenqing Ye; Shangqian Wang; Chun-Wu Pan; Yasheng Zhu; Yuqian Yan; Yinhui Yang; Di Wu; Yundong He; Jun Zhang; Daru Lu; Xiuping Liu; Long Yu; Shimin Zhao; Yao Li; Dong Lin; Yuzhuo Wang; Liguo Wang; Yu Chen; Yinghao Sun; Chenji Wang; Haojie Huang
Journal:  Nat Med       Date:  2017-08-14       Impact factor: 53.440

7.  Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Authors:  Xiangpeng Dai; Wenjian Gan; Xiaoning Li; Shangqian Wang; Wei Zhang; Ling Huang; Shengwu Liu; Qing Zhong; Jianping Guo; Jinfang Zhang; Ting Chen; Kouhei Shimizu; Francisco Beca; Mirjam Blattner; Divya Vasudevan; Dennis L Buckley; Jun Qi; Lorenz Buser; Pengda Liu; Hiroyuki Inuzuka; Andrew H Beck; Liewei Wang; Peter J Wild; Levi A Garraway; Mark A Rubin; Christopher E Barbieri; Kwok-Kin Wong; Senthil K Muthuswamy; Jiaoti Huang; Yu Chen; James E Bradner; Wenyi Wei
Journal:  Nat Med       Date:  2017-08-14       Impact factor: 53.440

8.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Authors:  Philipp Rathert; Mareike Roth; Tobias Neumann; Felix Muerdter; Jae-Seok Roe; Matthias Muhar; Sumit Deswal; Sabine Cerny-Reiterer; Barbara Peter; Julian Jude; Thomas Hoffmann; Łukasz M Boryń; Elin Axelsson; Norbert Schweifer; Ulrike Tontsch-Grunt; Lukas E Dow; Davide Gianni; Mark Pearson; Peter Valent; Alexander Stark; Norbert Kraut; Christopher R Vakoc; Johannes Zuber
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

9.  Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Authors:  Matthieu Le Gallo; Andrea J O'Hara; Meghan L Rudd; Mary Ellen Urick; Nancy F Hansen; Nigel J O'Neil; Jessica C Price; Suiyuan Zhang; Bryant M England; Andrew K Godwin; Dennis C Sgroi; Philip Hieter; James C Mullikin; Maria J Merino; Daphne W Bell
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

10.  Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Authors:  Shaokun Shu; Charles Y Lin; Housheng Hansen He; Robert M Witwicki; Doris P Tabassum; Justin M Roberts; Michalina Janiszewska; Sung Jin Huh; Yi Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G Stover; Muhammad B Ekram; Jonathan Brown; Clive D'Santos; Ian E Krop; Deborah Dillon; Michael McKeown; Christopher Ott; Jun Qi; Min Ni; Prakash K Rao; Melissa Duarte; Shwu-Yuan Wu; Cheng-Ming Chiang; Lars Anders; Richard A Young; Eric Winer; Antony Letai; William T Barry; Jason S Carroll; Henry Long; Myles Brown; X Shirley Liu; Clifford A Meyer; James E Bradner; Kornelia Polyak
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.